title: Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody.
abstract: Twenty-seven living-donor kidney recipients were treated with the antibody against CD25 as the induction immunosuppressive agent. They did not develop acute rejection within 1 month after transplantation, and mean serum creatinine level at 1 month was 1.0 +/- 0.4 mg/dL. There were no findings of acute rejection or drug-induced nephrotoxicity in protocol biopsies at 1 month following transplantation. After 1 month had passed, acute rejection occurred in three cases. The pathological grade of acute rejection varied from borderline to grade III by Banff classification. The careful inspection is necessary to find out the occurrences of acute rejection more than 2 months after transplantation because immunological situation has been changing around this period.
authors.affiliation: Department of Organ interaction Research Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. amoto@koto.kpu-m.ac.jp
authors.forename: Masahiko
authors.initials: M
authors.lastname: Okamoto
authors.forename: Kiyokazu
authors.initials: K
authors.lastname: Akioka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Higuchi
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Kadotani
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Ushigome
authors.forename: Kenji
authors.initials: K
authors.lastname: Uryuhara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kaihara
authors.forename: Norio
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab